Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jasper Dingemanse

Showing results (161-170 of 238) with videos related to

Pageof 24
Sort By:
Journal of Psychopharmacology (Oxford, England)|October 24, 2019
Clinical pharmacology of the dual orexin receptor antagonist ACT-541468 in elderly subjects: Exploration of pharmacokinetics, pharmacodynamics and tolerability following single-dose morning and repeated-dose evening administrationClemens Muehlan, Margaux Boehler, Sander Brooks, et al.
Biomolecules|September 28, 2023
Mind the Gap: Model-Based Switching from Selatogrel to Maintenance Therapy with Oral P2Y12 Receptor AntagonistsChih-Hsuan Hsin, Jasper Dingemanse, Andrea Henrich, et al.
British Journal of Clinical Pharmacology|October 22, 2009
Effect of the urotensin-II receptor antagonist palosuran on secretion of and sensitivity to insulin in patients with Type 2 diabetes mellitusPatricia N Sidharta, Klaus Rave, Lutz Heinemann, et al.
Paediatric Drugs|January 13, 2017
Pediatric Development of Bosentan Facilitated by Modeling and SimulationJochen Zisowsky, Martine Géhin, Andjela Kusic-Pajic, et al.
Journal of Clinical Pharmacology|May 12, 2024
Transfer of the Dual Orexin Receptor Antagonist Daridorexant into Breast Milk of Healthy Lactating WomenPriska Kaufmann, Clemens Muehlan, Marion Anliker-Ort, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|September 5, 2014
Mass balance, pharmacokinetics and metabolism of the selective S1P1 receptor modulator ponesimod in humansMaribel Reyes, Matthias Hoch, Patrick Brossard, et al.
British Journal of Clinical Pharmacology|April 11, 2016
Pharmacokinetics of the novel oral prostacyclin receptor agonist selexipag in subjects with hepatic or renal impairmentPriska Kaufmann, Hans G Cruz, Andreas Krause, et al.
Clinical and Translational Science|March 14, 2020
Effect of Rifampin-Mediated OATP1B1 and OATP1B3 Transporter Inhibition on the Pharmacokinetics of the P2Y12 Receptor Antagonist SelatogrelUta Schilling, Jasper Dingemanse, Christine Voors-Pette, et al.
British Journal of Clinical Pharmacology|July 18, 2017
Effect of gemfibrozil and rifampicin on the pharmacokinetics of selexipag and its active metabolite in healthy subjectsShirin Bruderer, Marc Petersen-Sylla, Margaux Boehler, et al.
Clinical Pharmacokinetics|May 18, 2021
Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability of Daridorexant, A Novel Dual Orexin Receptor AntagonistBenjamin Berger, Jasper Dingemanse, Giancarlo Sabattini, et al.
Pageof 24

Showing results (161-170 of 238) with videos related to

Sort By:
Pageof 24
Journal of Psychopharmacology (Oxford, England)|October 24, 2019
Clinical pharmacology of the dual orexin receptor antagonist ACT-541468 in elderly subjects: Exploration of pharmacokinetics, pharmacodynamics and tolerability following single-dose morning and repeated-dose evening administrationClemens Muehlan, Margaux Boehler, Sander Brooks, et al.
Biomolecules|September 28, 2023
Mind the Gap: Model-Based Switching from Selatogrel to Maintenance Therapy with Oral P2Y12 Receptor AntagonistsChih-Hsuan Hsin, Jasper Dingemanse, Andrea Henrich, et al.
British Journal of Clinical Pharmacology|October 22, 2009
Effect of the urotensin-II receptor antagonist palosuran on secretion of and sensitivity to insulin in patients with Type 2 diabetes mellitusPatricia N Sidharta, Klaus Rave, Lutz Heinemann, et al.
Paediatric Drugs|January 13, 2017
Pediatric Development of Bosentan Facilitated by Modeling and SimulationJochen Zisowsky, Martine Géhin, Andjela Kusic-Pajic, et al.
Journal of Clinical Pharmacology|May 12, 2024
Transfer of the Dual Orexin Receptor Antagonist Daridorexant into Breast Milk of Healthy Lactating WomenPriska Kaufmann, Clemens Muehlan, Marion Anliker-Ort, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|September 5, 2014
Mass balance, pharmacokinetics and metabolism of the selective S1P1 receptor modulator ponesimod in humansMaribel Reyes, Matthias Hoch, Patrick Brossard, et al.
British Journal of Clinical Pharmacology|April 11, 2016
Pharmacokinetics of the novel oral prostacyclin receptor agonist selexipag in subjects with hepatic or renal impairmentPriska Kaufmann, Hans G Cruz, Andreas Krause, et al.
Clinical and Translational Science|March 14, 2020
Effect of Rifampin-Mediated OATP1B1 and OATP1B3 Transporter Inhibition on the Pharmacokinetics of the P2Y12 Receptor Antagonist SelatogrelUta Schilling, Jasper Dingemanse, Christine Voors-Pette, et al.
British Journal of Clinical Pharmacology|July 18, 2017
Effect of gemfibrozil and rifampicin on the pharmacokinetics of selexipag and its active metabolite in healthy subjectsShirin Bruderer, Marc Petersen-Sylla, Margaux Boehler, et al.
Clinical Pharmacokinetics|May 18, 2021
Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability of Daridorexant, A Novel Dual Orexin Receptor AntagonistBenjamin Berger, Jasper Dingemanse, Giancarlo Sabattini, et al.
Pageof 24